STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
45.51 ^USD	+7.54%		+10.38%	+45.82%

21/06	STAAR Surgical Company Provides Information to the Shareholders	CI
12/06	Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM

Broadwood Partners Engages in Discussions with STAAR Surgical

January 29, 2021 at 03:56 am IST

On January 28, 2021, Broadwood Partners, L.P. announced that it has been and may continue to be in contact with members of STAAR Surgical Company's management, the board, other shareholders and others regarding alternatives that the Company could employ to create additional shareholder value over time.

Latest news about STAAR Surgical Company

STAAR Surgical Company Provides Information to the Shareholders	22/06	CI
Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	12/06
BTIG Upgrades STAAR Surgical to Buy From Neutral, Price Target is $46	11/06	MT
Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating	08/05	MT
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating	08/05	MT
Transcript : STAAR Surgical Company, Q1 2024 Earnings Call, May 07, 2024	08/05
STAAR Surgical Company Reports Earnings Results for the First Quarter Ended March 29, 2024	08/05	CI
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024	08/05	CI
STAAR Surgical Company Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision	08/05	CI
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel	01/05	CI
Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	11/04	MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	08/04	MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales	04/04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	04/04	MT
STAAR Surgical Reports Preliminary Fiscal Q1 Sales; Updates Fiscal 2024 Sales Outlook -- Shares Jump Pre-Bell	04/04	MT
STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024	04/04	CI
STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024	02/04	CI
STAAR Surgical Company Announces Board Changes	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Stifel Upgrades STAAR Surgical to Buy From Hold, Raises Price Target to $50 From $30	11/03	MT
Mizuho Securities Adjusts Price Target on STAAR Surgical to $45 From $50, Keeps Buy Rating	28/02	MT
Piper Sandler Cuts STAAR Surgical Price Target to $33 From $40, Maintains Neutral Rating	27/02	MT
STAAR Surgical Q4 Earnings, Revenue Rise	27/02	MT
Transcript : STAAR Surgical Company, Q4 2023 Earnings Call, Feb 26, 2024	27/02
STAAR Surgical Company Affirms Earnings Guidance for the Fiscal Year 2024	27/02	CI

Chart STAAR Surgical Company

Duration

Period

More charts

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Companyâs EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Sector

Medical Equipment, Supplies & Distribution

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for STAAR Surgical Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.51 USD

Average target price

51.68 USD

Spread / Average Target

+13.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STAAR SURGICAL COMPANY	+45.82%	2.24B
ABBOTT LABORATORIES	-4.72%	182B
MEDTRONIC PLC	-2.83%	103B
BECTON, DICKINSON AND COMPANY	-5.01%	66.94B
CENCORA, INC.	+15.53%	46.73B
DEXCOM, INC.	-8.53%	45.14B
HOYA CORPORATION	+5.82%	41.57B
METTLER-TOLEDO INTERNATIONAL, INC.	+17.67%	30.48B
TERUMO CORPORATION	+14.00%	24.26B
WEST PHARMACEUTICAL SERVICES, INC.	-8.08%	23.58B

Other Medical Equipment, Supplies & Distribution